MAPKAPK3 and Hepatic fibrosis: In conclusion, the active ingredient of RTT, β-sitosterol, alleviates liver fibrosis by reduction of inflammatory mediator release, and targeting MK3, while reducing the binding of MK3 to IκB and reducing the activation of the NK-κB pathway, thereby promoting apoptosis of HSC.